Drug-associated cholelithiasis: a case of sulindac stone formation and the incorporation of sulindac metabolites into the gallstones.
A case of drug-associated cholelithiasis (sulindac chlecystohepatolithiasis) in a 63-yr-old woman is reported. The patient was admitted to our hospital to undergo treatment for rheumatoid arthritis of 20 yr duration. She was treated with nonsteroidal anti-inflammatory drugs (NSAID: sulindac). Two months later, she presented with right upper quadrant pain. Diagnostic studies including ultrasonography (US), computed tomography (CT) and endoscopic retrograde cholangiography (ERC), led to the diagnosis of cholecystohepatolithiasis. She underwent cholecystectomy and choledochotomy with an extraction of intrahepatic stones. The intrahepatic stones were light yellow in color with a claylike appearance. Unexpectedly, an infrared spectroscopic analysis of the stone showed it to consist of sulindac metabolites. In addition, the dilated segment of the intrahepatic bile duct naturally returned to its normal size after the discontinuation of the drug administration. This is the first reported case of sulindac stone formation in the bile duct. No similar problems with other NSAIDs have been reported previously.
Tokumine
F
F
Department of Surgery, Prefectural Naha Hospital, Naha-city, Okinawa, Japan.
Sunagawa
T
T
Shiohira
Y
Y
Nakamoto
T
T
Miyazato
F
F
Muto
Y
Y
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002769:Cholelithiasis / Q000139:chemically induced* / Q000737:chemistry; D005260:Female; D006801:Humans; D008875:Middle Aged; D013055:Spectrophotometry, Infrared; D013467:Sulindac / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013467:Sulindac